Effectiveness of antidepressants in improving the prognosis of COVID-19: A systematic review and meta-analysis

被引:0
作者
Cobos-Campos, Raquel [1 ]
de Lafuente-Morinigo, Arantxa Saez [1 ]
Cordero-Guevara, Jose Aurelio [1 ]
Bermudez-Ampudia, Cristina [1 ]
Apinaniz, Antxon [1 ,2 ,3 ]
Parraza, Naiara [1 ]
机构
[1] Bioaraba Hlth Res Inst, Epidemiol & Publ Hlth Grp, Vitoria, Spain
[2] Aranbizkarra I Hlth Ctr, Osakidetza Basque Hlth Serv, Vitoria, Spain
[3] Univ Basque Country, Dept Prevent Med & Publ Hlth, Vitoria, Spain
来源
ATENCION PRIMARIA | 2024年 / 56卷 / 03期
关键词
Selective serotonin; reuptake inhibitors; Antidepressants; Covid-19; DEPRESSION;
D O I
10.1016/j.aprim.2023.102771
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective, and material and methods: A systematic review and meta-analysis was performed to evaluate the effectiveness of antidepressants in reducing the poor evolution of COVID-19 disease (a composite variable including death, hospitalization and need for mechanical ventilation), and mortality, according the guidelines for Systematic Reviews of Interventions published by the Cochrane library. Source of data: MEDLINE, EMBASE and COCHRANE LIBRARY were consulted up to February 25, 2022. Unpublished studies were searched on clinicaltrials.gov platform. Selection of studies: Seven masked and unmasked, observational and experimental studies evaluating death, hospitalization and need for mechanical ventilation were selected. A second subgroup analysis with mortality variable was performed. Data extraction: A full risk of bias assessment was performed addressing issues such as information and confounding bias. ROB2 and Robins-I tools for randomized and no randomized studies were employed respectively. In the quantitative analysis, the risk of publication bias, heterogeneity, estimation of pooled measure and a sensitivity analysis was performed. The pooled final measure was calculated as odds ratio with its correspondent 95% confidence interval. A random effects model was used for this purpose due to the heterogeneity between included studies. Finally, a sensitivity analysis was performed to assess the robustness of final pooled measure. Results: Seven studies were finally considered to calculate the final pooled measure. The effect of intervention was OR 0.73; 95% CI 0.56-0.94.
引用
收藏
页数:9
相关论文
共 40 条
  • [31] Depression in the Primary Care Setting
    Park, Lawrence T.
    Zarate, Carlos A., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (06) : 559 - 568
  • [32] Ongoing Use of SSRIs Does Not Alter Outcome in Hospitalized COVID-19 Patients: A Retrospective Analysis
    Rauchman, Steven H.
    Mendelson, Sherri G.
    Rauchman, Courtney
    Kasselman, Lora J.
    Pinkhasov, Aaron
    Reiss, Allison B.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (01)
  • [33] Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
    Reis, Gilmar
    dos Santos Moreira-Silva, Eduardo Augusto
    Medeiros Silva, Daniela Carla
    Thabane, Lehana
    Milagres, Aline Cruz
    Ferreira, Thiago Santiago
    Quirino dos Santos, Castilho Vitor
    de Souza Campos, Vitoria Helena
    Ribeiro Nogueira, Ana Maria
    Figueiredo Guimaraes de Almeida, Ana Paula
    Callegari, Eduardo Diniz
    de Figueiredo Neto, Adhemar Dias
    Monteiro Savassi, Leonardo Cancado
    Campos Simplicio, Maria Izabel
    Ribeiro, Luciene Barra
    Oliveira, Rosemary
    Harari, Ofir
    Forrest, Jamie, I
    Ruton, Hinda
    Sprague, Sheila
    McKay, Paula
    Glushchenko, Alla, V
    Rayner, Craig R.
    Lenze, Eric J.
    Reiersen, Angela M.
    Guyatt, Gordon H.
    Mills, Edward J.
    [J]. LANCET GLOBAL HEALTH, 2022, 10 (01): : E36 - E45
  • [34] The potential for strategies using micronutrients and heterocyclic drugs to treat invasive gliomas
    Rooprai, HK
    Christidou, M
    Pilkington, GJ
    [J]. ACTA NEUROCHIRURGICA, 2003, 145 (08) : 683 - 690
  • [35] Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
    Seftel, David
    Boulware, David R.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (02):
  • [36] Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
    Sukhatme, Vikas P.
    Reiersen, Angela M.
    Vayttaden, Sharat J.
    Sukhatme, Vidula V.
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [37] Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages
    Talmon, Maria
    Rossi, Silvia
    Pastore, Anna
    Cattaneo, Carlo Ignazio
    Brunelleschi, Sandra
    Fresu, Luigia Grazia
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (01) : 113 - 124
  • [38] Primary care responses to the COVID-19 pandemic
    Zeber, John E.
    Khanna, Niharika
    [J]. FAMILY PRACTICE, 2021, 38 : 1 - 2
  • [39] Antidepressants for COVID-19: A systematic review
    Zheng, Wei
    Sun, He-Li
    Cai, Hong
    Zhang, Qinge
    Ng, Chee H.
    Xiang, Yu-Tao
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2022, 307 : 108 - 114
  • [40] The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue
    Zimniak, Melissa
    Kirschner, Luisa
    Hilpert, Helen
    Geiger, Nina
    Danov, Olga
    Oberwinkler, Heike
    Steinke, Maria
    Sewald, Katherina
    Seibel, Juergen
    Bodem, Jochen
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)